
|Videos|September 21, 2016
Were PCSK9 Inhibitors Overhyped?
Author(s)Lauren Santye, Assistant Editor
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Erin Hohman, PharmD, BCPS, director of Clinical Pharmacy Services at Amber Pharmacy, discusses access to cholesterol-lowering PCSK9 inhibitors and whether the hype regarding the impact of these medications was overblown.
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Zidesamtinib for Previously Treated ROS1-Positive NSCLC
2
mRNA COVID-19 Booster Outperforms Protein-Based Shot on Antibodies, But Both Cut Infections Over 12 Months
3
Navigating REMS: Challenges, Perspectives, and the Path Forward for Bispecific Antibody Programs
4
Up to 5 Cups of Coffee Daily Safe—and Beneficial—for Most Adults
5











































































































